

Clinical Trials Summary for out of hours Important Reference

Acronym study title	ARTEMIDE 02 Lung Study
Study Details	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Principal Investigator PI Sub PI's	PI – Prof Ruth Board Sub Investigator – Dr Devleena, Dr Hadjiyiannakis, Dr Amin and Dr Lam
Research Nurse Team	Research Nurse – Jessica Westney CTA – Zahir Shah
Drug therapy	<ul style="list-style-type: none"> • Arm A (experimental arm): rilvegostomig 750 mg iv Q3W in combination with carboplatin AUC 6 iv Q3W and paclitaxel 200 mg/m² iv Q3W or nab-paclitaxel 100 mg/m² iv Day 1, 8, and 15 of each 3-week cycle for 4 cycles followed by rilvegostomig 750 mg iv Q3W. Use of carboplatin AUC 5 and/or paclitaxel 175mg/m² is permitted per local practice. • Arm B (control arm): pembrolizumab 200 mg iv Q3W in combination with carboplatin AUC 6 iv Q3W and paclitaxel 200 mg/m² iv Q3W or nab-paclitaxel 100 mg/m² iv Day 1, 8, and 15 of each 3-week cycle for 4 cycles followed by pembrolizumab 200 mg iv Q3W. Use of carboplatin AUC 5 and/or paclitaxel 175mg/m² is permitted per local practice.
In the event that a patient calls this hotline for advise	Contact the PI for sub-Investigators via hospital switchboard